title: Effects of topically administered FK506 on sciatic nerve regeneration and reinnervation after vein graft repair of short nerve gaps.
abstract: OBJECTIVE
  Despite the development of various nerve coaptation materials and techniques, achievement of desired functional peripheral nerve regeneration is still inadequate, and repair of peripheral nerve injuries is still one of the most challenging tasks and concerns in neurosurgery. The effect of an FK506-loaded vein graft as an in situ delivery system for FK506 in bridging the defects was studied using a rat sciatic nerve regeneration model.
  
  
  METHODS
  A 10-mm sciatic nerve defect was bridged using an inside-out vein graft (IOVG) filled with 10 μl of a carrier-drug dilution (10 ng/ml FK506) in the IOVG/FK506 group. In the IOVG control group, the vein was filled with the same volume of carrier dilution alone. The regenerated fibers were studied 4, 8, and 12 weeks after surgery.
  
  
  RESULTS
  Functional study confirmed faster recovery of the regenerated axons in the IOVG/FK506 group than in the IOVG group (p < 0.05). There was a statistically significant difference between the mean gastrocnemius muscle weight ratios of the IOVG/FK506 and IOVG control groups (p < 0.05). Morphometric indices of regenerated fibers showed that the number and diameter of the myelinated fibers were significantly higher in the IOVG/FK506 group than in the IOVG control group. Immunohistochemical analysis showed more positive immunoreactivity to S100 protein in the IOVG/FK506 group than in the IOVG control group.
  
  
  CONCLUSIONS
  When loaded in a vein graft, FK506 resulted in improvement of functional recovery and quantitative morphometric indices of sciatic nerve. Topical application of this readily available agent offers the benefit of cost savings as well as avoiding the complications associated with systemic administration.
authors.affiliation: Department of Clinical Sciences, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran. s.azizi@urmia.ac.ir
authors.forename: Saeed
authors.initials: S
authors.lastname: Azizi
authors.forename: Rahim
authors.initials: R
authors.lastname: Mohammadi
authors.forename: Keyvan
authors.initials: K
authors.lastname: Amini
authors.forename: Roza
authors.initials: R
authors.lastname: Fallah
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D004195:Disease Models, Animal; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D018482:Muscle, Skeletal / Q000473:pathology; D009416:Nerve Regeneration / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D020127:Recovery of Function / Q000187:drug effects; D009418:S100 Proteins / Q000378:metabolism; D020426:Sciatic Neuropathy / Q000188:drug therapy* / Q000601:surgery*; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D014182:Transplantation, Autologous / Q000379:methods; D014680:Veins / Q000166:cytology / Q000637:transplantation*
chemical_list: D007166:Immunosuppressive Agents; D009418:S100 Proteins; D016559:Tacrolimus